Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2014 / Jul / The battle for hearts and minds
Retina

The battle for hearts and minds

Population-level disease prophylaxis with statins has improved the lives of millions. But there has been some protest about this mass medication. Is the next battle not with disease, but with the press?

By Mark Hillen 7/31/2014 1 min read

Share

Delaying the onset of age-related ophthalmic diseases prolongs people’s quality of life, and shortens the time that they spend with visual impairment. There are also massive financial benefits to healthcare systems and society in general.
Postponing the day when dry AMD-related geographic atrophy begins to rob people of their vision by five to ten years would be an astonishing achievement. As Cécile Delcourt describes in her article in this month’s issue, lifelong nutrition plays a rôle. The majority of the public haven’t had an optimally nutritious and balanced diet from an early age, so for them, rest-of-life nutritional supplementation is currently their only option for prophylaxis. What they need is a pill; an ocular equivalent of statins for the prevention of cardiovascular events.

Statins have become the subject of a great deal of hue and cry in the media over their side-effect rates (miraculously small, relative to most other drugs) and the sheer number of people that could receive them: in the UK, 11 percent of the population are currently eligible to do so. Statins are also interesting to examine in terms of AMD; their use has been associated with delayed AMD development, and rumors exist of various post-statin drugs that interfere with cholesterol transport potentially being evaluated for prophylaxis against dry AMD. If they are effective, how likely is it that their side-effect profile will be as safe as statins? If it’s worse than statins, what will the tabloids like  the Daily Mail or the Düsseldorf Express – and large sections of the public – make of it?

From my perspective, effective, widespread, population-level prophylactic interventions hold the potential to dramatically improve health and quality of life for the greatest possible number of people. But to make that happen, I forsee issues. If statin use can be assaulted by an ever-increasingly antagonistic press, then I can see a harsher reception for anything with a sub-statin safety profile. Having said that, vaccinations – the single best and safest public health intervention possible – attract highly-motivated campaigners against their use. So perhaps the biggest battle will be not against disease, but for people’s hearts and minds.

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: